Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
July 19, 2023
Kaden Venugopal
1 citation
Introduction: Major depressive disorder (MDD) is a prevalent and complex mood disorder. Its psychotherapies often involve delayed treatment-response times, while its pharmacotherapies can cause unwanted side effects. In recent years, there has been a resurgence in psychedelic research with a specific interest in the potential of psilocybin for treating MDD. Therefore, this systematic review was...
Psychological Medicine
July 19, 2023
Brandon Weiss, Induni Ginige, Lu Shannon et al.
1 citation
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
International Journal of Gynecological Cancer
July 18, 2023
Dan Yaniv, L. Ramondetta, L. Cohen et al.
Women with gynecologic cancers face various physical and psychological challenges throughout their treatment journey. Late stages associated with poor prognosis, along with chronic side effects of treatment, often leave women with existential uncertainty stemming from unpredictable disease trajectory and continuous fear of death. Recently, a patient in her late 30s (JN) with endstage ovarian...
Journal of community genetics
July 17, 2023
Sarah Velissaris, Marie‐Claire Davis, Fiona Fisher et al.
People with Huntington's disease (HD) face difficult emotional and practical challenges throughout their illness, including in the pre-symptomatic stage. There are, however, extremely limited psychosocial interventions adapted to or researched for HD. We adapted and piloted an 8-week mindfulness-based stress reduction (MBSR) program in people with pre-symptomatic HD to determine if the program...
Clinical Psychopharmacology and Neuroscience
July 17, 2023
B. McCarthy, Hannah Bunn, Morgan Santalucia et al.
Depression is a significant cause of morbidity and mortality globally. Although various pharmacologic options exist for depression, treatments are limited by delayed or incomplete therapeutic response, low rates of remission, and adverse effects necessitating effective, fast-acting, and better tolerated alternatives. The purpose of this review is to describe the safety and efficacy of...
BMC Complementary Medicine and Therapies
July 17, 2023
Jojo Yan Yan Kwok, Man Auyeung, Shirley Yin Yu Pang et al.
6 citations
Between 40 and 50% of patients with Parkinson's disease (PD) experience anxiety and depression, associated with impaired physical function, high care dependency and mortality. Recently, the United States National Institutes of Health has urged the implementation of mindfulness practices in chronic illness care. Most research to date has examined the effects on chronically ill patients of...
Journal of Affective Disorders
July 15, 2023
Matthew B. Wall, Cynthia Lam, Natalie Ertl et al.
36 citations
Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following PT. Brain responses to music were assessed before and after PT using...
The British Journal of Psychiatry
July 14, 2023
Colleen Loo, N. Glozier, David Barton et al.
70 citations
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed. Aims To assess the acute efficacy and safety of a 4-week course of subcutaneous racemic ketamine in participants with TRD. Trial registration: ACTRN12616001096448 at www.anzctr.org.au. Method This phase 3,...
Open Access Government
July 13, 2023
Cosmo Feilding-Mellen
Using psychedelics to mitigate Treatment Resistant Depression Cosmo Feilding-Mellen, CEO, Beckley Psytech, charts the role of psychedelics in mitigating Treatment Resistant Depression. When it comes to treating neuropsychiatric and mental health conditions, we have to accept that one size does not fit all. For some, talking therapies like cognitive behavioural therapy plus antidepressants like...
Nature
July 13, 2023
Rich Haridy
55 citations
Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed. Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed.
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 13, 2023
Dimitri Daldegan-Bueno, Natalia Maria Simionato, Vanessa Manchim Favaro et al.
18 citations
The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. Animal models are essential to investigate the pharmacological effects of ayahuasca since they can control important factors influencing it, such as the set and setting. Review and summarise data available on ayahuasca research using animal models. We systematically searched five databases (PubMed,...
International Clinical Psychopharmacology
July 11, 2023
Lucas Arrighi, Eloïse Maakaron, Théo Korchia et al.
About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD...
Frontiers in Neuroscience
July 11, 2023
Maria Gałuszko‐węgielnik, Katarzyna Jakuszkowiak‐wojten, Mariusz S. Wiglusz et al.
8 citations
Background: Psychotic treatment-resistant depression represents a complex and challenging form of mood disorder in clinical practice. Despite its severity, psychotic depression is frequently underdiagnosed and inadequately treated. Ketamine has demonstrated rapid and potent antidepressant effects in clinical studies, while exhibiting a favorable safety and tolerability profile. Although there...
British medical journal
July 11, 2023
B. Nogrady
18 citations
The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...
Clinical Psychopharmacology and Neuroscience
July 10, 2023
Jeongseop Kim, Tae-Eun Kim, Seung Hwan Lee et al.
29 citations
The monoamine hypothesis has significantly improved our understanding of mood disorders and their treatment by linking monoaminergic abnormalities to the pathophysiology of mood disorders. Even 50 years after the monoamine hypothesis was established, some patients do not respond to treatments for depression, including selective serotonin reuptake drugs. Accumulating evidence shows that patients...
Vertex Revista Argentina de Psiquiatría
July 10, 2023
Tamara Chernoff, Bruno Kliger, Dante Hernán Venturini
Traditional psychedelics, such as LSD, psilocybin, or DMT, are psychoactive compounds that exert their effects mainly through agonism over serotonergic receptors. In appropriate doses and contexts, they produce profound changes in the subjective experience, configuring altered states of consciousness that, upon reaching a critical point, involve the appearance of phenomena of mystical,...
American Journal of Geriatric Psychiatry
July 8, 2023
Giacomo D’andrea, Stefania Chiappini, Roger S McIntyre et al.
36 citations
INTRODUCTION: Treatment-resistant depression (TRD) is a serious and debilitating psychiatric disorder that frequently affects older patients. Esketamine nasal spray (ESK-NS) has recently been approved as a treatment for TRD, with multiple studies establishing its efficacy and tolerability. However, the real-world effectiveness, tolerability, and safety of this treatment in older adults is still...
International Clinical Psychopharmacology
July 7, 2023
Nicola Ragone, Barbara Barbini, Carolina Passani et al.
More than 10 years ago, the discovery of the antidepressant effects of Ketamine opened the opportunity to develop a novel class of antidepressants. Ketamine induces dissociative symptoms as a major side effect. This rapid-acting antidepressant is available as an endovenous racemic compound and as an intranasal S-enantiomer: Esketamine; which is four-fold more potent for the NMDA receptor. Here...
Drugs & therapy perspectives
July 6, 2023
Hannah A. Blair
Dextromethorphan/bupropion (AUVELITY®), an oral, fixed-dose combination of dextromethorphan hydrobromide and bupropion hydrochloride, is a useful treatment option for adults with major depressive disorder (MDD). Dextromethorphan is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist. The antidepressant bupropion (an aminoketone and cytochrome P450 2D6...
International Journal of Clinical and Health Psychology
July 5, 2023
Yanjuan Li, Ruilin Ju, Stefan G Hofmann et al.
Background Both trait and state mindfulness are associated with less depression and anxiety, but the mechanisms remain unknown. Distress tolerance, an important transdiagnostic factor of emotional disorders, may mediate the relationship between mindfulness and depression/anxiety. Method Study 1 examined the mediation model at the between-person level in a large cross-sectional sample (n = 905)....